ArminGhobadiMD

Hematologic Oncology

Assistant Professor of Medicine, Division of Medical Oncology

Dr. Ghobadi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2006 - 2009
Iran University of Medical SciencesClass of 2001

PubMed

1281 citations
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis
The Lancet. Oncology. 2019-01-01
1731 citations
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee, Bianca Santomasso, Frederick L. Locke, Armin Ghobadi, Cameron J. Turtle
Biology of Blood and Marrow Transplantation. 2019-04-01
583 citations
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
John S. Welch, Allegra A. Petti, Christopher A. Miller, Catrina Fronick, Michelle O'Laughlin
The New England Journal of Medicine. 2016-11-23

Journal Articles

Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published Data
Francesca Ferraro, Peter Westervelt, John F Dipersio, Armin Ghobadi, Leukemia Research

Abstracts/Posters

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...
Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published DataAugust 2018

Simple Blood Test Helps Identify Patients Developing Neurotoxic Side EffectsSeptember 8th, 2022
FDA Grants Orphan Drug Status to CAR-T for T-cell Acute Lymphoblastic LeukemiaMarch 18th, 2022
Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBLMarch 15th, 2022
Join now to see all